Verition Fund Management
COGT icon

Verition Fund Management’s Cogent Biosciences COGT Stock Holding History

Verition Fund Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07M Buy
+105,102
New +$3.68M 0.02% 747
2026
Q1 		– Sell
-59,456
Closed -$2.11M – 2513
2025
Q4 		$2.11M Buy
59,456
+42,342
+247% +$1.19M 0.01% 1556
2025
Q3 		$246K Sell
17,114
-81,475
-83% -$965K ﹤0.01% 3391
2025
Q2 		$708K Buy
98,589
+56,760
+136% +$315K ﹤0.01% 2718
2025
Q1 		$251K Sell
41,829
-21,695
-34% -$170K ﹤0.01% 2945
2024
Q4 		$495K Buy
63,524
+32,296
+103% +$322K ﹤0.01% 2495
2024
Q3 		$337K Buy
31,228
+2,176
+7% +$21.2K ﹤0.01% 2565
2024
Q2 		$245K Buy
29,052
+18,204
+168% +$138K ﹤0.01% 2474
2024
Q1 		$72.9K Buy
+10,848
New +$67.1K ﹤0.01% 2612
2023
Q2 		– Sell
-11,920
Closed -$129K – 2248
2023
Q1 		$129K Buy
+11,920
New +$152K ﹤0.01% 1878

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Verition Fund Management's COGT Position: Q2 2026 in Review

Verition Fund Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 105,102 shares worth $4.07M. The stake represents 0.02% of the portfolio and ranks #747 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in COGT as recently as Q4 2025.

Verition Fund Management first reported a position in COGT in Q1 2023 and has held it in 10 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Verition Fund Management held 105,102 shares of Cogent Biosciences worth $4.07M as of Q2 2026.
  • Cogent Biosciences was a new Verition Fund Management position in Q2 2026.
  • Cogent Biosciences made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #747 holding.
  • Verition Fund Management first reported a position in Cogent Biosciences in Q1 2023 and has held it in 10 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.